<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Interleukin-6 (IL-6) appears to be involved in the <z:mp ids='MP_0001845'>inflammatory response</z:mp> associated with central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Although IL-6 levels increase after <z:hpo ids='HP_0001297'>stroke</z:hpo>, it is not known whether IL-6 directly influences <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> ischemic injury </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we used a focal reversible <z:hpo ids='HP_0001297'>stroke</z:hpo> model to investigate whether mice lacking IL-6 were protected against <z:hpo ids='HP_0011009'>acute</z:hpo> ischemic injury </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We bred IL-6-deficient C57 black mice (I-129 IL-6 KO back-crossed with C57), including homozygous knockouts (IL-6 -/-), heterozygous littermates (IL-6 +/-), and <z:mpath ids='MPATH_458'>normal</z:mpath> littermates (IL-6 +/+) </plain></SENT>
<SENT sid="4" pm="."><plain>The status of <z:hpo ids='HP_0000001'>all</z:hpo> animals was confirmed by DNA sampling and polymerase chain reaction analysis </plain></SENT>
<SENT sid="5" pm="."><plain>Reversible middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> was produced by advancing a <z:chebi fb="144" ids="48140">silicone</z:chebi>-coated 8-0 filament into the internal carotid artery for 2 hours (experiment 1) or 45 minutes (experiment 2) </plain></SENT>
<SENT sid="6" pm="."><plain>At 24 hours, animals were evaluated on a 28-point clinical scale, blood and cerebrospinal fluid were obtained, and the brains were evaluated for <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and IL-6 mRNA levels </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: In experiment 1 (severe <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>), no differences were seen in lesion size or neurological function between the groups: lesion volume was IL-6 -/- (n=15), 57+/-13 mm(3); IL-6 +/- (n=15), 58+/-23 mm(3); and IL-6 +/+ (n=15), 58+/-18 mm(3) (P=NS) </plain></SENT>
<SENT sid="8" pm="."><plain>ELISA testing confirmed very low to absent levels of IL-6 in the serum and cerebrospinal fluid of knockout animals </plain></SENT>
<SENT sid="9" pm="."><plain>Brain <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of the other proinflammatory cytokines, including <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha, IL-1beta, and IL-1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, were 50% lower in IL-6-deficient ischemic animals than in <z:mpath ids='MPATH_458'>normal</z:mpath> animals </plain></SENT>
<SENT sid="10" pm="."><plain>In experiment 2 (mild <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>), no differences were seen in lesion size or neurological function between the groups: lesion volume was IL-6 -/- (n=10), 16+/-8 mm(3); IL-6 +/- (n=10), 14+/-4 mm(3); and IL-6 +/+ (n=10), 19+/-12 mm(3) (P=NS) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: In this study, <z:mpath ids='MPATH_124'>infarct</z:mpath> size and neurological function at 24 hours were not different in animals deficient in IL-6 after transient <z:mp ids='MP_0006080'>CNS ischemia</z:mp> </plain></SENT>
<SENT sid="12" pm="."><plain>This suggests that IL-6 does not have a direct influence on <z:hpo ids='HP_0011009'>acute</z:hpo> ischemic injury </plain></SENT>
<SENT sid="13" pm="."><plain>Further study investigating the role of IL-6 on long-term recovery after <z:hpo ids='HP_0001297'>stroke</z:hpo> is in progress </plain></SENT>
</text></document>